What's in BioXcel Therapeutics's pipeline?

BioXcel Therapeutics has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with BioXcel Therapeutics's portfolio?

Top competitors by shared drug class: Lavipharm, Legacy Pharma Usa, Promius Pharma.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/bioxcel.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

BioXcel Therapeutics — Portfolio Competitive Intelligence Brief

BioXcel Therapeutics (BTAI) pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

BTAI (NASDAQ) 1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Precedex	dexmedetomidine	marketed	Central alpha-2 Adrenergic Agonist	Alpha-1D adrenergic receptor	Neuroscience	1999-01-01

Therapeutic area mix

Neuroscience · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Lavipharm · 1 shared drug class
Legacy Pharma Usa · 1 shared drug class
Promius Pharma · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for BioXcel Therapeutics:

Cite this brief

Drug Landscape (2026). BioXcel Therapeutics — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bioxcel. Accessed 2026-05-14.